Millie
your market intelligence analyst
Search Results
212 results
Your search is now limited to «Amgen» expert search.
STAT 08/23/2019 09:45
Two of India’s biggest drug makers are allegedly giving gifts and cash to encourage “quack” doctors to prescribe vast amounts of antibiotics.
More from STAT:
FiercePharmaManufacturing 08/23/2019 09:36
Rumors that Amgen is looking to prop up its top and bottom lines by buying Alexion have been floating around for more than a year.
More from FiercePharmaManufacturing:
Investor's Business Daily 08/22/2019 16:08
Biotech giant Amgen (AMGN) could be nearing a deal to buy Alexion Pharmaceuticals (ALXN) at a 74% premium, according to a Spanish news outlet.
More from Investor's Business Daily:
ENDPOINTS 08/22/2019 10:47
Novartis may have given up, but Amgen and Allergan are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States. Their copycat, ABP 798, was found to have a impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients.
More from ENDPOINTS:
PR Newswire 08/22/2019 09:00
About Amgen Biosimilars Amgen is committed to building upon Amgen's experience in the development and manufacturing of innovative human therapeutics to expand Amgen's reach to patients with serious illnesses.
More from PR Newswire:
Zacks.com 08/22/2019 09:00
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Amgen imply an improvement in the company's underlying business.
More from Zacks.com:
Market Exclusive 08/21/2019 08:18
Analyst Ratings For Amgen, Inc. (NASDAQ:AMGN) Today, Royal Bank of Canada raised its price target on Amgen, Inc. (NASDAQ:AMGN) to $192.00 per share. There are 9 Buy Ratings, 8 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amgen, Inc. (NASDAQ:AMGN) is Buy with a consensus target […]. .
More from Market Exclusive:
BioPharma Dive 08/19/2019 11:25
Amgen's aggressive strategy appears to be paying off, as favorable court decisions and the backing of a major insurer have strengthened Amgen's hand.
More from BioPharma Dive:
As we previously reported, after Amgen obtained FDA-approval for MVASI (bevacizumab-awws), a biosimilar of Genentech’s AVASTIN, Amgen submitted—and the FDA approved—a number of supplements that revised, among other things, manufacturing and labeling information for the product.
More from Goodwin Procter BioSimilars Blog:
24/7 Wall Street 08/16/2019 09:05
The top analyst upgrades, downgrades and initiations on Friday included Alibaba, Amgen, Applied Materials, Intel, Merck, Nvidia and Walmart.
More from 24/7 Wall Street:
BioPharma-Reporter 08/13/2019 10:45
Immunex Corporation and Amgen Manufacturing, affiliates of Amgen, and the owner and licensor of the two patents, Hoffmann-La Roche brought the patent infringement action to the federal court.
More from BioPharma-Reporter:
CNBC - Market Insider 08/12/2019 12:58
Amgen — Shares of Amgen surged more than 5% after the biotech company won a lawsuit Friday that would protect the two patents on its rheumatoid arthritis drug Enbrel, according to a press release.
More from CNBC - Market Insider:
Pharmafile 08/12/2019 04:47
A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel.
More from Pharmafile:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications